Lollo CP - Search Results

1

Obstacles and advances in non-viral gene delivery.

Lollo CP, Banaszczyk MG, Chiou HC. Lollo CP, et al. Curr Opin Mol Ther. 2000 Apr;2(2):136-42. Curr Opin Mol Ther. 2000. PMID: 11249633 Review.

2

Gene therapy strategies for the treatment of chronic viral hepatitis.

Chiou HC, Lucas MA, Coffin CC, Banaszczyk MG, Ill CR, Lollo CP. Chiou HC, et al. Among authors: lollo cp. Expert Opin Biol Ther. 2001 Jul;1(4):629-39. doi: 10.1517/14712598.1.4.629. Expert Opin Biol Ther. 2001. PMID: 11727499 Review.

3

Poly-L-lysine-based gene delivery systems. Synthesis, purification, and application.

Lollo CP, Banaszczyk MG, Mullen PM, Coffin CC, Wu D, Carlo AT, Bassett DL, Gouveia EK, Carlo DJ. Lollo CP, et al. Methods Mol Med. 2002;69:1-13. doi: 10.1385/1-59259-141-8:001. Methods Mol Med. 2002. PMID: 11987770 No abstract available.

4

Stabilization of poly-L-lysine/DNA polyplexes for in vivo gene delivery to the liver.

Kwoh DY, Coffin CC, Lollo CP, Jovenal J, Banaszczyk MG, Mullen P, Phillips A, Amini A, Fabrycki J, Bartholomew RM, Brostoff SW, Carlo DJ. Kwoh DY, et al. Among authors: lollo cp. Biochim Biophys Acta. 1999 Feb 16;1444(2):171-90. doi: 10.1016/s0167-4781(98)00274-7. Biochim Biophys Acta. 1999. PMID: 10023051

5

Strength of conjugate binding to plasmid DNA affects degradation rate and expression level in vivo.

Mullen PM, Lollo CP, Phan QC, Amini A, Banaszczyk MG, Fabrycki JM, Wu D, Carlo AT, Pezzoli P, Coffin CC, Carlo DJ. Mullen PM, et al. Among authors: lollo cp. Biochim Biophys Acta. 2000 Sep 1;1523(1):103-10. doi: 10.1016/s0304-4165(00)00104-5. Biochim Biophys Acta. 2000. PMID: 11099863

6

Non-viral gene delivery: vehicle and delivery characterization.

Lollo CP, Kwoh DY, Mockler TC, Ley PM, Guido MS, Coffin CC, Aleman R, Bartholomew RM, Carlo DJ. Lollo CP, et al. Blood Coagul Fibrinolysis. 1997 Dec;8 Suppl 2:S31-8. Blood Coagul Fibrinolysis. 1997. PMID: 9607111

7

An open-label, randomized, single-dose, two-period, two-treatment crossover bioavailability study comparing 5 mg/0.5 mL of intramuscular naloxone hydrochloride to 2 mg/0.4 mL intramuscular naloxone hydrochloride autoinjector in healthy subjects.

Moss RB, Carleton F, Lollo CP, Carlo DJ. Moss RB, et al. Among authors: lollo cp. J Opioid Manag. 2020 May/Jun;16(3):209-214. doi: 10.5055/jom.2020.0569. J Opioid Manag. 2020. PMID: 32421841 Clinical Trial.

8

DNA condensation for gene therapy as monitored by atomic force microscopy.

Hansma HG, Golan R, Hsieh W, Lollo CP, Mullen-Ley P, Kwoh D. Hansma HG, et al. Among authors: lollo cp. Nucleic Acids Res. 1998 May 15;26(10):2481-7. doi: 10.1093/nar/26.10.2481. Nucleic Acids Res. 1998. PMID: 9580703 Free PMC article.

9

Liver toxicity induced by combined external-beam irradiation and radioimmunoglobulin therapy.

Wang S, Quadri SM, Tang XZ, Stephens LC, Lollo CP, Bartholomew RM, Vriesendorp HM. Wang S, et al. Among authors: lollo cp. Radiat Res. 1995 Mar;141(3):294-302. Radiat Res. 1995. PMID: 7871156

10

90Yttrium antiferritin--a new therapeutic radiolabeled antibody.

Order SE, Klein JL, Leichner PK, Frincke J, Lollo C, Carlo DJ. Order SE, et al. Int J Radiat Oncol Biol Phys. 1986 Feb;12(2):277-81. doi: 10.1016/0360-3016(86)90110-0. Int J Radiat Oncol Biol Phys. 1986. PMID: 3005201

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

15 results

Search Page